
From: [REDACTED] <[REDACTED]@gsk.com>
Sent: Tuesday, September 8, 2020 10:51 AM
To: [REDACTED] (COMP) <[REDACTED]@ec.europa.eu>;
sandra.gallina@ec.europa.eu
Cc: [REDACTED] <[REDACTED]@sanofi.com>; [REDACTED] <[REDACTED]@gsk.com>; [REDACTED] <[REDACTED]@sanofi.com>;
[REDACTED] <[REDACTED]@gsk.com>; [REDACTED] <[REDACTED]@gsk.com>; [REDACTED] <[REDACTED]@sanofi.com>;
[REDACTED] <[REDACTED]@sanofi.com>

Subject: proposed options on post approval studies

Dear [REDACTED] and Mrs Gallina

Prior to our discussion later today please find attached the thinking of Sanofi/GSK partners on costs for PMC.

Kind regards

[REDACTED]

[REDACTED]

GSK
Avenue Fleming 20
Building W23
1300 Wavre

[REDACTED]

GSK monitors email communications sent to and from GSK in order to protect GSK, our employees, customers, suppliers and business partners, from cyber threats and loss of GSK Information. GSK monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation.